FDA rejects Portola's anticoagulant antidote AndexXa

18 August 2016
2019_biotech_test_vial_discovery_big

The US Food and Drug Administration has turned down approval of Portola Pharmaceuticals’ (Nasdaq: PTLA) anticoagulant antidote product for the time being, sending the company’s shares down 11% to $23.69 in regular trading on Wednesday, and the stock was 17.7% lower at $19.50 in pre-market trading today.

The FDA issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for AndexXa (andexanet alfa).

An FDA-designated Breakthrough Therapy, AndexXa is in development for patients treated with a direct (apixaban, Bristol-Myers and Pfizer’s Eliquis, rivaroxaban, Bayer’s Xarelto, or edoxaban) or indirect (enoxaparin) Factor Xa inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology